biostudies-literatureGold JAWCenters for Disease Control and Preventionofac215https://www.ebi.ac.uk/biostudies/studies/S-EPMC9253885biostudies-literatureUnknown9(7)<h4>Background</h4>Invasive mold diseases (IMDs) cause severe illness, but public health surveillance data are lacking. We describe data collected from a laboratory-based, pilot IMD surveillance system.<h4>Methods</h4>During 2017-2019, the Emerging Infections Program conducted active IMD surveillance at 3 Atlanta-area hospitals. We ascertained potential cases by reviewing histopathology, culture, and <i>Aspergillus</i> galactomannan results and classified patients as having an IMD case (based on European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group [MSG] criteria) or a non-MSG IMD case (based on the treating clinician's diagnosis and use of mold-active antifunOpen forum infectious diseasesClinical Characteristics, Health Care Utilization, and Outcomes Among Patients in a Pilot Surveillance System for Invasive Mold Disease-Georgia, United States, 2017-2019.PMC9253885CDC-RFA-CK17-1701Lockhart SRGold JAWPouch SMMontero AJOliver NTRevis AJordan ABerkow ELLysen CBeer KDThomas SBlakney RAChambers TFarley MMPerry LWebster ASBentz MLKelly HCJackson BRNunnally NSfalseClinical Characteristics, Health Care Utilization, and Outcomes Among Patients in a Pilot Surveillance System for Invasive Mold Disease-Georgia, United States, 2017-2019.<h4>Background</h4>Invasive mold diseases (IMDs) cause severe illness, but public health surveillance data are lacking. We describe data collected from a laboratory-based, pilot IMD surveillance system.<h4>Methods</h4>During 2017-2019, the Emerging Infections Program conducted active IMD surveillance at 3 Atlanta-area hospitals. We ascertained potential cases by reviewing histopathology, culture, and <i>Aspergillus</i> galactomannan results and classified patients as having an IMD case (based on European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group [MSG] criteria) or a non-MSG IMD case (based on the treating clinician's diagnosis and use of mold-active antifun2022-01-01T00:00:00Z2022 Jul2025-04-26T13:04:38.837Z2022-07-21T10:45:16.53ZS-EPMC92538853579494510.1093/ofid/ofac215